![]() ![]() Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. Proc Natl Acad Sci USA 2003 100: 2610–2615.īennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. N Engl J Med 1979 301: 5–8.īaechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Immune interferon in the circulation of patients with autoimmune disease. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. These results provide a unique genomic view of ex vivo IFN-α response in two lupus-prone models, and help to have an insight into the role of IFN-α in lupus pathogenesis Interestingly, the splenic mononuclear cells from the NZB/W not MRL/lpr lupus-prone mice at the pre-autoimmune stage before ex vivo IFN-α treatment, have increased expression of many known IFN-regulated genes. Of IFN-α-induced genes differentially expressed in NZB/W vs BALB/c and MRL/lpr mice at 3 h time point, enhanced expression of CCND1, cyclin D2, matrix metalloproteinase 13 and a panel of cytokines and chemokines and impaired expression of negative inflammatory regulators CD69 and an Src family kinase hemopoietic cell kinase were notable. ![]() Analysis of IFN-α-induced gene expression patterns revealed genes associated with antiproliferative activity of IFN-α including CDKN1A, GADD45B, pituitary tumor-transforming 1, SCOTIN, ataxia telangiectasia-mutated homolog and calcyclin-binding protein were upregulated in MRL/lpr and/or BALB/c mice. To understand this paradox, we examined the kinetic global gene expression in pre-autoimmune NZB/W-, MRL/lpr- and normal BALB/c-derived splenic mononuclear cells following ex vivo IFN-α treatment. Studies in murine lupus models have revealed that type I IFN exerts either a protective effect in MRL/lpr, or can detrimentally impact disease progression, as in NZB/W mice. Interferon (IFN)-α is involved in the pathogenesis of systemic lupus erythematosus. ![]()
0 Comments
Leave a Reply. |